Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Neurotensin is an endogenous tridecapeptide neuropeptide first identified in extracts of bovine hypothalamus. It acts as a neurotransmitter and neuromodulator in the central nervous system and periphery. Neurotensin exerts its biological effects primarily through two G protein-coupled receptors, NTS1 and NTS2. It modulates dopaminergic signaling, influences thermoregulation (can induce hypothermia), provides neuroprotection in models of cerebral ischemia, and is a potent mitogen for colorectal cancer cells. Neurotensin has been implicated in the pathophysiology of several conditions including schizophrenia (as an endogenous antipsychotic-like agent), substance use disorders, pain modulation (analgesic effects independent of opioids), cancer proliferation (notably colorectal cancer), and uterine fibroids[1][2][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on neurotensin.